Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.37 |
| ▸ | NPY1R | P25929 | 10/20 | 0.37 |
| ▸ | NPY2R | P49146 | 7/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13662423 | 0.83 | NPY4R (0.38) | NPY4RNPY5RNPY1RNPY2RALB | |
| SCHEMBL2742864 | 0.80 | NPY4R (0.38) | NPY4RNPY5RNPY1RNPY2RSIRT5 | |
| SCHEMBL10082825 | 0.78 | NPY4R (0.39) | NPY4RNPY5RNPY1RNPY2RSIRT5 | |
| SCHEMBL24306834 | 0.75 | NPY4R (0.38) | NPY4RNPY5RNPY1RNPY2RSIRT5 | |
| SCHEMBL16359252 | 0.75 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RSIRT5 | |
| SCHEMBL6382960 | 0.73 | NPY4R (0.42) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL1724846 | 0.72 | FOLH1 (0.40) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL4552682 | 0.72 | FOLH1 (0.40) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL24900018 | 0.72 | SIRT5 (0.49) | NPY4RNPY5RNPY1RNPY2RSIRT5 | |
| SCHEMBL1934309 | 0.72 | SIRT5 (0.49) | NPY4RNPY5RNPY1RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003636-B2 | Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090203578-A1 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | NPY4R 695/4885NPY5R 711/4885NPY1R 951/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | NPY4R 4012/4885NPY5R 4592/4885NPY1R 4691/4885 |
| US-20090203578-A1 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE | CYP46A1, CYP2F1, LIPA | NPY4R 4433/4885NPY5R 3328/4885NPY1R 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.